Frost & Sullivan Independent Equity Research
Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre- IND (505(b)(2) submission; Target price remains unchanged.
![dnaLogo dnaLogo](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/dnaLogo-nx7oepmjwr0nqu046yc3t5fs9jyo1sg30b9j97epgk.png)
Company: D.N.A.-Entera
Sector: Healthcare
Report type: Q1-2018 Update
Published on: 10 June, 2018